

# Special Issue

## Targeted Therapy in Sarcoma

### Message from the Guest Editors

In this Special Issue, a collection of studies on the current state of preclinical and clinical investigations shall be assembled. Studies that investigate new promising therapeutic targets, pathways, or innovative surgical approaches, as well as submissions that evaluate targeted therapies in combination with immuno-therapy and/or conventional systemic therapies, are encouraged. The aim is to summarize the interdisciplinary nature of sarcoma treatment, with a focus on targeted therapeutic strategies.

Potential topics include, but are not limited to, the following:

- Current and new therapeutic targets in specific sarcoma subtypes;
- Diagnosis and selection of patients with sarcoma for targeted therapy;
- Targeted operative therapy;
- Individual sarcoma therapy;
- Role of the immune system in the setting of targeted therapy;
- Implications of the combination of targeted therapy with immune-therapies and/or conventional chemotherapies.

---

### Guest Editors

Prof. Dr. Thiha Aung  
Dr. Anna Duprée  
Prof. Dr. Silke Haerteis

---

### Deadline for manuscript submissions

closed (30 July 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/143998](https://mdpi.com/si/143998)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)